Anthony Purchio, PhD, has been named chief scientific officer for Numira Biosciences (Irvine, California). Previously, Purchio was VP and chief scientific officer at Xenogen. Numira is a specialty R&D tools company focused on advances in genetics and molecular imaging.

• Pathwork Diagnostics (Sunnyvale, California), a genomics-based diagnostics company focused on oncology, has expanded its executive team, it said, to prepare for commercialization of its first product. W. David Henner, MD, PhD, was named chief medical officer, and David Craford was named VP, commercial operations. Henner was previously VP of oncology at Novacea. Craford most recently was VP of business development at Affymetrix. The company’s first test, the Pathwork Tissue of Origin Test, is under FDA review for the diagnosis of patients with uncertain primary cancers, in which a tumor’s origin cannot be readily identified.

No Comments